Gamble of the week: ground-breaking biotech stock

By Paul Hill Oct 02, 2009

Paul Hill

Share with
friends:

Comments (0) Print this article

Unless you're a medical expert, you'll probably never have heard of ISIS Pharmaceuticals. But in five to ten years' time, assuming things go according to plan, this biotech outfit could be a household name. That's because it has developed a ground-breaking new technique called 'antisense'.

Many of today's most common diseases such as cardiovascular problems, cancer and diabetes are caused by 'bad' proteins being wrongly produced in the human body. Current drugs attack these dangerous cells, but the problem is that the side effects can be extreme, and the efficacy poor.

In contrast, antisense operates one step ahead in the DNA chain. It stops these disease-causing proteins from ever being generated by turning off the genes that encode the protein. This means none of the 'good' cells are harmed, so the side effects are far fewer, and the treatment can be tailored to each individual patient.

ISIS owns 1,600 patents and currently has 19 drugs in the pipeline, most of which are being jointly developed with partners such as Genzyme, Bristol-Myers Squibb and Novartis.

ISIS Pharmaceuticals (Nasdaq: ISIS)

ISIS's first potential blockbuster drug is Mipomersen, which is aimed at cutting cholesterol levels. It's presently undergoing Phase III clinical trials; submission to the US regulator, the FDA, is set for 2010. So far the results have been very encouraging. The chief executive said in August that "key opinion leaders with whom we have shared the detailed data are thrilled".

Assuming he's right, and the FDA approves Mipomersen in 2011, shares could rocket overnight. A positive verdict would not only give the green light to this specific treatment, but would more importantly provide a huge endorsement to the whole antisense drug class. There's also no danger of patent expiries until 2023 at the earliest, and the group has $500m in net cash (or $5 a share) to fund itself for the foreseeable future.

What are the potential pitfalls? As with most early-stage biotechs, ISIS is still loss making and its success depends on one main therapeutic area. But with antisense being such a breakthrough, ISIS looks a good bet on the long-term growth in personalised medicine and ageing populations, along with being a takeover target for Big Pharma.

Recommendation: speculative BUY at $14.50 (market capitalisation $1.4bn)

• Paul Hill also writes a weekly share-tipping newsletter, Precision Guided Investments

Comments (0)

Published in Tips & advice | More articles by Paul Hill

Share with
friends:

Related articles

Leave a comment

This will be the name displayed with your comment.

This helps us verify comments are genuine. It will not be displayed anywhere on the site and is stored confidentially.

Please keep your comment within 1,000 characters and relevant to the main topic. We encourage healthy debate, but we don't allow insults or bad language. Anything off topic or unpleasant, we'll remove. Enjoy the conversation! Thank you.

captcha To prevent spam-related comments please enter the characters shown in the 'Captcha' box to the left.

By leaving a comment you accept our terms and conditions.


FREE - MoneyWeek's daily investment emailJohn Stepek

Our free daily email, Money Morning, is an informative and enjoyable analysis of what's going on in the markets. Written by our Editor, John Stepek, and guest contributors.
Sign up FREE to Money Morning here.

>